|Wellcome Sanger Institute||Head of technology Transfer||United Kingdom|
WHAT IS THE RIGHT BALANCE BETWEEN EQUITY, ROYALTIES AND COLLABORATIVE RESEARCH INCOME FOR ACADEMIC INSTITUTIONS THAT ARE IN THE PROCESS OF SPINNING OUT COMPANIES?
Adrian has 20 year’s experience of commercialising academic innovation. Adrian joined the Sanger Institute in 2011 to establish the Technology Translation Office. With a background spanning academic research, structured finance and technology commercialisation, Adrian was recruited to optimise the ability of Sanger Institute science to support delivery of healthcare benefit. Since Adrian’s arrival Sanger has experienced significant expansion and maturation of the Institute’s portfolio of spin out companies, establishment of the paradigm changing Open Targets initiative and execution of major strategic licensing deals. Adrian has lead the Innovation Strategy underpinning the Campus Vision to develop the Wellcome Genome Campus into an international hub for scientific, business, educational and cultural activities flowing from genome sciences and biodata. Adrian chairs the UK BioIndustry Association Genomics Advisory Committee, sits on spin out company boards and is chair of the Sanger Translation Committee Fund.